帕金森病的刚性:莱沃多巴的客观效应
Marco Falletti1, Francesco Asci1, Alessandro Zampogna1,2
1Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
概括
利沃多巴有效地通过改善客观测量来减少帕金森硬度,特别是在更高的运动速度时. 这项研究量化了勒沃多巴对帕金森病患者硬度和长延迟反射的神经元件的影响.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 临床神经学 临床神经学
背景情况:
- 对莱沃多巴对帕金森病 (PD) 硬度的影响的定量证据有限.
- 最近的研究强调了PD刚性的速度依赖性和神经基础.
研究的目的:
- 调查勒沃多巴对帕金森病患者硬度的客观测量的影响.
主要方法:
- 18名PD患者在OFF和ON两种状态下进行了评估.
- 通过使用机器人辅助的手腕延伸在各种角度速度 (5-280°/s) 上进行临床和仪器评估刚性.
- 表面电肌图测量了短时间和长时间的延伸反射 (SLR和LLR).
主要成果:
- 利沃多巴改善了临床刚性得分,并减少了力量的神经元件.
- 利沃多巴降低了LLR的速度依赖性,但没有影响SLR.
- 在临床改善和生物机械/神经生理学变化之间发现了显著的相关性.
结论:
- 列沃多巴通过减少其神经元件和LLRs来缓解PD中的客观刚性.
- 利沃多巴对刚性的有益影响在更高的角速度时更加明显.
- 这些发现为PD刚性病理生理学的新模型做出了贡献.
相关概念视频
Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
252
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
252
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Antipsychotic Drugs: Therapeutic Uses and Side Effects
119
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
119


